Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Roche Glycart

Request full access

Provider of in vitro diagnostics and provide transformative solutions for key therapeutic areas

Zurich, SwitzerlandFounded 2000Biotech & Life Sciences

About Roche Glycart

Roche Glycart AG operates as a center of excellence for cancer immunotherapy research and antibody engineering within the Roche Group. The company originated as GlycArt Biotechnology AG, a spin-off from the Swiss Federal Institute of Technology (ETH) in Zurich, founded in September 2000. Key founders include Dr. Pablo Umaña and Joël Jean-Mairet. Dr. Umaña's doctoral research at Caltech and ETH Zurich on the glycoengineering of antibodies formed the scientific basis for the company's core technology.

In July 2005, Roche acquired GlycArt Biotechnology for approximately 235 million Swiss francs, integrating it into its Pharma Research and Early Development (pRED) division. This acquisition was a strategic move for Roche to secure GlycArt's proprietary GlycoMAb® technology and its pipeline of preclinical antibody candidates for oncology. Post-acquisition, the entity became the Roche Innovation Center Zurich, focusing on developing new cancer medicines. The business is centered on research and development, specifically creating new potent antibody-based products to treat cancer.

The company's core offering is its GlycoMAb® technology platform, which modifies the carbohydrate component of therapeutic antibodies to boost their natural cell-killing mechanism, known as antibody-dependent cellular cytotoxicity (ADCC). This glycoengineering process enhances the potency of antibodies, making them more effective at destroying targeted cancer cells. The technology is applicable to various antibody types and can be implemented in standard production cell lines without disrupting productivity. A significant achievement stemming from this technology is the drug Gazyva (obinutuzumab), which in 2013 became the first medicine approved by the FDA under its Breakthrough Therapy designation for treating chronic lymphocytic leukemia. Since the acquisition, the team has grown from 29 to over 180 employees, all based in Schlieren, Switzerland.

Source: Dealroom company data

At a glance

Status
Acquired
Employees
2
Open positions
None listed
Dealroom signal
52.8/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Spinout, Hard Tech, DT and LS, science-based, Swiss DT Biotech
Business model
Manufacturing

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITION✓Exit Jul 2005 $0 — Undisclosed —
SERIES A✓Equity / VC Nov 2003 $14M $54M Novartis Venture Fund —
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Roche Glycart website traffic

Latest recorded traffic for Roche Glycart is 25K monthly website visits, down 21.9% over the last three months. Roche Glycart's team grew 0% over the past year.

Latest monthly visits25K 3-month web change-21.9% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Roche Glycart in the Zurich ecosystem

Live from Dealroom

The Roche Glycart office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

8 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • Novartis Venture Fund

Other known investors7 additional known investors

  • ETH Zurich
  • BioMedVC
  • Deutsche Venture Capital
  • Forbion Capital Partners
  • Gilde Healthcare
  • Global Life Science Ventures
  • Quest Capital Management
Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇭 Switzerland · Zurich HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Roche Glycart on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Roche Glycart’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.